A Study of KW-3357 in Congenital Antithrombin Deficiency
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the pharmacokinetics, safety and tolerability of
KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.